After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses;

2025/06/2507:36:43 hotcomm 1337

Recently, industry media Fierce Pharma released the latest "Global Top 10 Vaccine Companies Ranking" . The new crown epidemic has "spite" the entire industry. Compared with the last ranking in 2017, the list is almost completely reshuffled.

After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews

*Editor's note: The data comes from public documents and is uniformly converted into US dollars based on the average exchange rate in 2021.

companies whose rankings are rising:

Pfizer is the most eye-catching existence on the list. In one and a half years (2021+2022H1), the vaccine product revenue is nearly 68 billion US dollars, which is no less than the annual revenue of a top pharmaceutical company. It is a well-deserved global vaccine leader.

The rankings of enterprises declined:

MSD , GSK and Sanofi and Sanofi , lost in the "New Coronavirus Speed ​​Race", and its rankings declined one after another, ranking fifth, sixth and seventh.

It is worth noting that although they did not receive the most COVID dividends, their stable R&D pipeline and global leading product advantages are still difficult to easily break through by later generations.

New companies on the list:

BioNTech Under the leadership of the "boss" Pfizer, it has become the second place among the global vaccine giants from obscurity.

Chinese enterprise KSING Biotech Sales in 2021 exceeded US$19 billion, overwhelming a number of old vaccine giants, counterattacked the list, ranking third in the world.

"fight alone" Moderna is defeated by BioNTech, which is backed by a big tree. The revenue difference between the two in 2021 is nearly US$5 billion, ranking fourth.

Zhifei Bio revenue last year was US$4.75 billion, becoming China's top two vaccine companies to be among the top 10 in the world. The "hot product" HPV vaccine (agent Merck products) made an indelible contribution.

Under the supermarket brought by the epidemic, the vaccine industry has been upside down. Many previously unknown people took advantage of the situation to the top, which also allows people to see the huge potential of China and low- and middle-income countries behind the counterattack of Sinovac and Zhifei Bio.

However, there is still a long way to practice from "upstarts" to "giants". The pandemic will eventually become history, but the myth of the vaccine industry will not end. Whether it has the strength of hard-core R&D and whether it can supplement a relatively single pipeline in time determines the future time for Chinese upstarts to stay on the list.

  • Pfizer Pharmaceuticals (Pfizer)

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews021 Vaccine revenue: US$42.63 billion

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews022 Vaccine revenue in the first half of the year: US$25.4 billion

    Business person: Vaccine manager Nanette Cocero

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews

    It is not surprising that Pfizer has reached the "peak" of the vaccine industry.

    After obtaining the FDA emergency use authorization in December 2020, the COVID-19 vaccine jointly developed by Pfizer and BioNTech like a rocket:

    • In 2021, the sales of the vaccine were close to 37 billion , and the output was close to 3 billion doses; in 2022, 4 billion doses are expected to be produced.

      • Before The new crown , Pfizer's vaccine business centered on Prevnar 13 - one of the best-selling vaccines in the world. In 2019, the vaccine revenue was US$5.85 billion, accounting for about After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews9% of the total revenue of Pfizer vaccine .

      Nowadays, even if the pandemic has subsided, Pfizer still expects revenue to continue to increase.

      Comirnaty is still moving forward.

      • After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews months, the FDA approved the vaccine for preschoolers at least 6 months old, which had been approved in children between 6 and 17 years of age.
      • htmlIn August, the FDA approved Pfizer and Moderna's reinforcement needle for omicron.

      In addition to Comirnaty, Pfizer recently released positive phase 3 data on its respiratory syncytial virus (RSV) vaccine, hoping to get approval by next year to join the competition with GSK and Johnson & Johnson .

      According to a report by SVB Leerink analysts, Pfizer RSV vaccine revenue will reach 2.1 billion by 2030.

      In addition, Pfizer received FDA approval last year for the next generation of pneumococcal vaccine Prevnar 20, which can attack 20 different bacterial strains.

      BioNTech

      After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews021 Vaccine revenue: US$22.48 billion

      After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews022 Vaccine revenue in the first half of the year: US$10.3 billion

      Business person: CEO Uğur Şahin

      After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews

      BioNTech shared profits with Pfizer on COVID-19 vaccine Comirnaty, and performed slightly better than its competitor Moderna in terms of revenue. Its full-year revenue of 19 billion euros .

      Looking ahead, BioNTech is expected to have revenue of 13-17 billion euros this year.

      PopularThe surge in performance in the first few years will not last forever. Given that most of the world “decided to coexist with the virus”, researchers expect that BioNTech will receive approximately 14 billion euros in revenue in 2022, which is at the low level expected by BioNTech.

      In addition to COVID, BioNTech's oncology pipeline is being "established", and its partners include Roche and Regeneron, and the R&D results are expected to be gradually disclosed starting from 2024.

    Sinovac (Sinovac)

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews021 Vaccine revenue: US$19.37 billion

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews022 Vaccine revenue in the first half of the year: Undisclosed

    Business person: Chairman and CEO Yin Weidong

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews

    In 2021, Sinovac Biotech's sales almost quadrupled, surpassing Moderna, ranking among the top 3 vaccine manufacturers in the world in revenue . Similarly, Sinovac's new crown vaccine CoronaVac is the main driving force for the surge.

    Relying on CoronaVac, Sinovac Bio's revenue growth rate is amazing

    • 019, revenue was US$246 million
    • 020, revenue was US$511 million
      • 021, revenue was US$19.37 billion

    This vaccine was specially approved in China in August 2020 for vaccination in high-risk groups such as medical professionals. In February 2021, the scope of use was expanded to the public through a conditional marketing authorization.

    Recently, Sinovac Biotech was approved to start clinical trials of omicron enhancement injections in China and Chile . At the same time, trivalent vaccines against the original coronavirus strain and delta and omicron variants are being developed.

    But as vaccine penetration becomes higher and competition intensifies, Sinovac Biotech may not be able to maintain the same income level in 2022.

    In addition to COVID, Sinovac Biotech also has vaccines for seasonal and pandemic influenza, polio , hepatitis A and B, and pneumococcal disease. Its product line includes recombinant HBV vaccine, HAV and HBV combined vaccine, adsorption tetanus vaccine, Hib-bound vaccine, etc.

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews

    Moderna

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews021 Vaccine revenue: US$17.67 billion

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews022 Vaccine revenue in the first half of the year: US$10.82 billion

    Business person: CEO Stéphane Bancel

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews

    Moderna ranks second in the world in COVID-19 vaccine production. Ranked fourth in revenue.

    In 2021, Moderna fulfilled its promise, and Spikevax achieved

  • 7.67 billion vaccine sales, accounting for the majority of the company's total revenue of $18.47 billion. Spikevax is still accelerating in the first half of this year, generating $10.5 billion in sales. According to pre-orders, the company expects sales data in the second half of 2022 to be close to it.

    Moderna’s approval is for adults aged 18 and older, while Pfizer covers adults aged 12 and older.

    In addition to Spikevax, Moderna is also developing influenza vaccines. CEO Stéphane Bancel has said he believes the vaccine can provide 90% of its efficacy, which will be a huge improvement to the current product.

    , Moderna vaccinated the first patients in the Phase 3 influenza trial, with Pfizer following the development of the mRNA flu vaccine.

    In the early stage pipeline, Moderna is studying the influenza-COVID combination vaccine and the influenza , COVID and RSV combination vaccine.

    In addition, vaccines for HIV, human herpes virus , varicella zoster, Zika virus and Nipah virus are under development.

    Merck Sharp & Dohme

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews021 Vaccine revenue: US$9.69 billion

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews022 Vaccine revenue in the first half of the year: US$4.97 billion

    Business person: CEO Robert Davis

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews

    Msody, as the world's largest vaccine manufacturer, has "dominated" the industry for several years, but the new crown epidemic has changed this industry structure.

    When the epidemic began, the industry had high expectations for it, but Merck had no choice but to miss the dividends of the entire new crown vaccine and gave up two projects shortly after Pfizer and Moderna obtained the FDA authorization.

    Based on revenue in 2021, Merck did not continue to maintain the dominance of the world's largest vaccine seller, but instead ranked fifth with US$9.69 billion revenue.

    However, will undoubtedly rank at the top if COVID vaccine sales are excluded from the top 10. Merck's vaccine revenue in the first half of this year was $4.97 billion, and it may see new growth this year.

    Merck's "famous actress" Gardasil continued to dominate the HPV field for $5.7 billion last year, a major rebound after 2020, when sales were $3.9 billion. Gardasil continued to grow rapidly in the first half of 2022, with sales reaching $3.1 billion.

    Mx believes that as more production plans go online, sales of Gardasil may double by 2030.

    Other blockbuster vaccine products:

    • ProQuad for preventing measles , mumps , rubella and chickenpox , and Varivax, which only prevents chickenpox, had a total revenue of $2.1 billion last year. It was a modest rebound after the pandemic slowed down, with sales reaching $1.9 billion.
    • vaccine for preventing young children's rotavirus RotaTeq continues to climb steadily, reaching US$807 million by 2021. Since 2015, revenue from the vaccine has grown every year.

    Merck's next-generation pneumococcal vaccine Vaxneuvance was well underway, and received key pediatric approval in June. It has an advantage over Pfizer's vaccine and prevents 15 serotypes (13 for Prevnar), which could be favored before Pfizer's next-generation vaccine Prevnar 20 is approved by the FDA.

    GlaxoSmithKline (GlaxoSmithKline)

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews021 Vaccine revenue: US$9.32 billion

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews022 Vaccine revenue in the first half of the year: US$4.22 billion

    Business person: Vaccine manager Roger Connor

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews

    GSK and Sanofi failed to succeed in the early cooperation in the field of COVID-19, resulting in the two companies losing their lead in the new crown competition. In 2021, GSK vaccine sales ranked sixth in the world, second only to four COVID-19 vaccine manufacturers and Merck.

    However, this does not mean that GlaxoSmithKline has not had a successful vaccine team. GSK vaccine products brought in £6.8 billion (about $9.3 billion) in revenue last year.

    And, despite the failure of cooperation with Sanofi, the cooperation with Medicago did win. Earlier this year, Medicago's COVID-19 vaccine Covifenz was approved for marketing in Canada, which contains adjuvant GSK, and is preparing to submit approval to other regions.

    Last year, GSK

    • meningitis vaccine revenue was £961 million (US$1.31 billion).
    • Influenza business revenue was £679 million.
    • "matured vaccine" has earned up to £2.97 billion in revenue, including hepatitis vaccines as well as infant vaccines and boosters.

    At present, perhaps the most important product of GSK is Shingrix. After approval in 2017, the shingles vaccine has achieved tremendous developments before the pandemic broke out. Now, GSK is redoubled its efforts to “re-launch” the blockbuster product with the goal of achieving around £4 billion in sales in 2026 (the vaccine will have £1.72 billion in 2021).

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews

    Sanofi(Sanofi)

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews021 Vaccine revenue: US$7.45 billion

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews022 Vaccine revenue in the first half of the year: US$2.32 billion

    Business person: Vaccine manager Thomas Triomphe

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews

    Sanofi remains the world's leading vaccine manufacturer in the flu; the company expects 2022 to be a "record" year.

    Last year, Sanofi's flu vaccine brought 2.63 billion euros, a year-on-year increase of 6%. That revenue grew by about $3.1 billion, based on the average euro-dollar exchange rate last year.

    All of the company's vaccines achieved sales growth in 2021, driving the group's overall revenue to 6.32 billion euros (US$7.45 billion).

    During the pandemic, Sanofi's vaccine business also experienced some executive turnover.

    • In May 2020, Sanofi vaccine director David Loew resigned and became the CEO of French biopharmaceutical company Ipsen. At the time, Sanofi appointed Thomas Triomphe as its vaccine leader, who joined Sanofi's vaccine group in 2004 and served as head of franchise and product strategy before the promotion.

    In February this year, Sanofi updated its corporate brand and logo, and the entire company will be unified under one Sanofi banner, including the business units currently focusing on vaccines and professional care, Sanofi Pasteur and Sanofi Ginseng, as well as all other acquired brands, will be merged into a single Sanofi name and brand.

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews

    Zhifei Bio

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews021 Vaccine revenue: US$4.75 billion

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews022 Vaccine revenue in the first half of the year: US$2.56 billion

    Business person: Chairman and President Jiang Rensheng

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews

    Zhifei Bio is the Chinese agent of Merck's HPV vaccines Gardasil and Gardasil 9.Since Gardasil and Gardasil 9 were approved in China in 2017 and 2018, it has been difficult to meet the strong domestic demand.

    HPV vaccine has become the cornerstone of Zhifei's business. Before reached a Gardasil agreement with Merck in 2018, Zhifei's revenue hovered at around 700 million yuan. In 2020, total revenue soared to 15.2 billion yuan.

    According to Zhifei's annual report, in 2021, the number of releases of Gardasil 9 doubled to 10.2 million doses.

    upward trend continued until 2022, with Gardasil 9 almost quadrupled in the first half of 2022 to about 9.3 million doses.

    htmlIn August, Gardasil 9's target population expanded from women aged 16-26 to women aged 9 to 45, and Gardasil is expected to achieve another growth breakthrough.

    In 2021, the cooperation with Merck brought Zhifei Bio's sales to RMB 20.9 billion, a year-on-year increase of 50%. In the first half of 2022, sales of these vaccines were RMB 16.7 billion, an increase of 134% year-on-year.

    Zhifei also has a product portfolio independently developed, and the revenue of the business increased to 9.7 billion yuan in 2021, thanks in part to the recombinant COVID-19 vaccine, which was approved for use in China in March 2021, and earlier this year, its authorization was expanded to a strengthening agent.

    In addition to COVID, Zhifei's listed products also include ACYW-135 vaccine, Hib vaccine, etc.

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews

    AstraZeneca (Astra Zeneca)

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews021 Vaccine revenue: US$3.98 billion

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews022 Vaccine revenue in the first half of the year: US$1.6 billion

    Business person: CEO Pascal Soriot

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews

    Although the sales of the COVID-19 vaccine Vaxzevria have been successfully achieved, AstraZeneca's time in the spotlight of the new crown vaccine may be about to end.

    AstraZeneca CEO Pascal Soriot told earlier this summer Reuters that AstraZeneca is considering a small acquisition in its established therapeutic areas such as cardiovascular disease and tumors, and is considering a complete divestment of the vaccine business.

    Although AstraZeneca's COVID-19 vaccine is one of the first to attract attention, it is always under the shadow of mRNA vaccines.

    In the early stages of the launch of AstraZeneca vaccine , supply shortages triggered a conflict between AZ executives and European officials. Shortly thereafter, people began to worry about the efficacy of vaccines in the elderly.

    As of now, the AstraZeneca COVID-19 vaccine has not been approved by the FDA.

    AstraZeneca's plan to divest the vaccine business should not be very shocking. In November, AstraZeneca revealed that it was spinning off a separate department to manage its COVID-19 products, including its vaccines, to better respond to the new crown epidemic.

    In addition to COVID-19, AstraZeneca also offers a Fluenz Tetra/FluMist Quadrivalent intranasal flu vaccine. Browse the AstraZeneca pipeline, no vaccine is among them except Vaxzevria.

  • 0

    JPJP (Johnson & Johnson)

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews021 Vaccine revenue: US$2.39 billion

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews022 Vaccine revenue in the first half of the year: US$1 billion

    Vaccine revenue in the first half of the year: US$1 billion

    Vaccine person in charge: Jansen Global Vaccine Director Penny Heaton

    After obtaining the FDA emergency use authorization in December 2020, Pfizer's COVID-19 vaccine developed like a Rocket: in 2021, the vaccine had sales of nearly $37 billion and production of nearly 3 billion doses; - DayDayNews

    The COVID-19 vaccine launched by Johnson & Johnson has safety and manufacturing problems and has not met the initial expectations.

    The product had revenue of US$2.39 billion in 2021. Although it is quite impressive, this number is not impressive for a company with annual revenue of US$93.77 billion.

    In February 2021, Johnson & Johnson received FDA approval for its first dose of COVID-19 vaccine. At that time, many people believed that Johnson & Johnson's dosage advantage would be a big benefit.

    But shortly after its launch, the United States stopped vaccination due to concerns about rare blood clots.

    In April 2022, Johnson & Johnson said it would not include COVID-19 vaccines in revenue forecasts, when the product received only $457 million in revenue.

    But this does not mean the end of Johnson & Johnson's vaccine ambitions.

    In 2018, Johnson & Johnson opened a factory in Netherlands to produce clinical trial doses of candidate drugs for HIV, respiratory syncytial virus , Ebola virus , Zika virus and influenza. Johnson & Johnson spent 4 years and 72 million euros to build the plant.

    At the same time, the RSV competition is getting more and more intense, and Johnson and Johnson are scrambling to promote R&D progress. A report by SVB Leeerink analysts said Johnson and Johnson expects to receive $1.7 billion through its vaccine candidate by 2030.

    Reference article: The top 10 vaccine companies worldwide

    https://www.fiercepharma.com/pharma/top-10-vaccine-companies-worldwide#27666ccc-3e69-47f9-9b95-857432c98d87

    • hotcomm Category Latest News

    hotcomm video recommendation

    USU and China trade spotlight - DayDayNews USU and China trade spotlight - DayDayNews

    USU and China trade spotlight...
    55:01
    Underground market-demo video - DayDayNews Underground market-demo video - DayDayNews

    Underground market-demo video...
    1:54
    What is the Company behind the WLGS Stock Ticker? about Wang & Lee Group - DayDayNews What is the Company behind the WLGS Stock Ticker? about Wang & Lee Group - DayDayNews

    What is the Company behind the WLGS Stock Ticker? ...
    9:30
    Welcome to our production workshop！ - DayDayNews Welcome to our production workshop！ - DayDayNews

    Welcome to our production workshop！...
    0:24
    China's 'uneven' recovery will show in market performance later this year: Fund manager - DayDayNews China's 'uneven' recovery will show in market performance later this year: Fund manager - DayDayNews

    China's 'uneven' recovery will show in market perf...
    1:52
    What lead to Chinese stock selloff? - DayDayNews What lead to Chinese stock selloff? - DayDayNews

    What lead to Chinese stock selloff?...
    2:43
    Meet the CEO: Wang Ming Chieh Explains the Vision Behind ShareAFunds - DayDayNews Meet the CEO: Wang Ming Chieh Explains the Vision Behind ShareAFunds - DayDayNews

    Meet the CEO: Wang Ming Chieh Explains the Vision ...
    1:31
    China is a short to medium-term trade, says Hightower's Stephanie Link - DayDayNews China is a short to medium-term trade, says Hightower's Stephanie Link - DayDayNews

    China is a short to medium-term trade, says Highto...
    3:59
    Stocks Rally fro the Week on Fed Rate-Cut Optimism | Bloomberg: The Close 9/27/2024 - DayDayNews Stocks Rally fro the Week on Fed Rate-Cut Optimism | Bloomberg: The Close 9/27/2024 - DayDayNews

    Stocks Rally fro the Week on Fed Rate-Cut Optimism...
    1:31:49
    Biden Slams Trump For Wanting Stock Market To 'Crash' - DayDayNews Biden Slams Trump For Wanting Stock Market To 'Crash' - DayDayNews

    Biden Slams Trump For Wanting Stock Market To 'Cra...
    0:48